Lead Sponsor

Aptabio Therapeutics, Inc.

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

•Clinical Diagnosis of type 2 diabetes and nephropathy
•First morning void (FMV) UACR between 200 and 3000 mg/g, inclusive
•30 mL/min/1.73m2 ≤ eGFR ≤ 90 mL/min/1.73m2 using CKD-EPI formula at screening
•HbA1c ≤ 10% at screening visit
•Subject who has been taking unchanged dosage of ACE inhibitor or ARB medication for at least 3 months prior to screening and is not anticipated to change its dosage during the course of the study
•Willing to be under dietary management for diabetes

•History of type 1 diabetes mellitus or gestational diabetes
•Subject's renal impairment and/or albuminuria is considered to be of origin other than Diabetic Kidney Disease
•Subject with uncontrolled blood pressure
•Clinically significant abnormal laboratory findings
•History of any cardiovascular event within 6 months prior to screening or cardiovascular procedure planned during the clinical trial
•Diagnostic or interventional procedure requiring a contrast agent within 4 weeks before the screening visit or planned during the course of the study
•Clinically significant ECG abnormalities on a 12-lead ECG at the screening visit or before randomization
•Current or history of NYHA class IV heart failure